QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study

An Observational Prospective Clinical Study to Assess Clinical Performance of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 Target in the Intended Use Population and Environment

This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method

This multicentre study aims to evaluation the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method

Inclusion Criteria:

• Presenting with signs and symptoms of a respiratory infection.
• Consent or assent to be obtained
• Able to communicate (speak, read and write) in local language, and able to understand and sign the required study documents.
• Willing and able to provide Nasopharyngeal Swab (NPS) Specimen collected per manufacturer's instructions.

Exclusion Criteria:

• Subjects who, in the opinion of the Investigator, are unsuitable for participation in the study.